Pharmaceutical composition containing PGI2 receptor stimulant and application thereof

Through the combination of PGI2 receptor agonist compounds and sildenafil, especially at specific molar ratios, the problem of poor effectiveness of existing drugs for treating pulmonary hypertension is solved, and stronger anti-pulmonary hypertension and inhibition of smooth muscle cells is achieved. The synergistic effect of proliferation provides a more effective treatment plan.

CN119033791AActive Publication Date: 2024-11-29SHIJIAZHUANG NO 4 PHARMACEUTICAL CO LTD +1

Patent Information

Application Number
CN202411212107.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-02-06
Filing Date
2024-08-30
Publication Date
2024-11-29
Estimated Expiration
2044-08-30

AI Technical Summary

Technical Problem

Existing drugs for treating pulmonary hypertension are not effective in long-term use, and the lack of effective combinations of drugs to reverse or prevent disease progression, making it difficult for treatment to meet clinical needs.

Method used

Using a pharmaceutical composition, including the PGI2 receptor agonist compound and sildenafil, the anti-pulmonary hypertension activity is enhanced and the K+-induced pulmonary artery is inhibited by using a combination of different molar ratios (such as 1:3-10:1). Increased ring tension and PDGF-induced proliferation of human pulmonary artery smooth muscle cells.

Benefits of technology

Significantly enhance the therapeutic effect on pulmonary hypertension, especially in moderate to severe cases where existing drugs cannot control, providing stronger synergies, significantly better than single or other combination drugs such as selepag and sildena Non-effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033791A_ABST
    Figure CN119033791A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of medicines, and particularly relates to a pharmaceutical composition containing a PGI2 receptor stimulant and application of the pharmaceutical composition. The pharmaceutical composition formed by combining the PGI2 receptor agonist compound shown in the general formula I or the pharmaceutical salt thereof and sildenafil has a synergistic effect on inhibiting K < + > induced pulmonary artery ring tension increase and / or inhibiting PDGF induced human pulmonary artery smooth muscle cell proliferation; the drug combination pharmaceutical composition is more helpful for treating diseases of patients with pulmonary arterial hypertension which cannot be controlled by a single drug. The synergistic effect of the combined drug composition on inhibition of K < + > induced pulmonary artery ring tension increase and / or inhibition of PDGF induced human pulmonary artery smooth muscle cell proliferation under a specific ratio and a test concentration is stronger than the synergistic effect of the existing drug composition selexipag and sildenafil. Therefore, the drug combination pharmaceutical composition with a specific proportion and a test concentration is more beneficial to treatment of diseases of moderate and severe pulmonary hypertension patients whose conditions cannot be controlled by the existing drug combination of selexipag and sildenafil.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to Chinese patent application CN202311824286.0, filed on December 27, 2023. This application claims priority to Chinese patent application CN202410169645.1, filed on February 6, 2024. This application cites the full text of the above-mentioned Chinese patent application. Technical Field

[0002] The present invention belongs to the field of drug combination, and specifically relates to a pharmaceutical composition comprising a PGI2 receptor agonist and a use thereof. Background Art

[0003] Pulmonary arterial hypertension (PAH) is a progressive, life-threatening disease characterized by vasoconstriction and vascular remodeling (i.e., intimal hyperplasia, medial hypertrophy, fibrosis) within the pulmonary arterioles, leading to a progressive increase in mean pulmonary artery pressure (mPAP) and pulmonary vascular resistance (PVR), often resulting in fatal right heart failure. The pathogenesis of PAH is not fully defined. Endothelial damage caused by external stimuli (e.g., hypoxia or anorexia) or systemic processes (e.g., connective tissue diseases) triggers a neurohormonal imbalance in susceptible individuals and is considered to be the focus or nitric oxide of disease progression. The result is an overproduction of mediators, such as endothelin-1, angiotensin II, thromboxane A2, and serotonin, leading to vasoconstriction, smooth muscle cell proliferation, and increased profibrotic and / or prothrombotic effects. Concomitantly, the production of nitric oxide (NO) and prostacyclin (PGI2) is reduced, and the imbalance of these mediators ultimately leads to pulmonary arterial vasculopathy.

[0004] The mechanisms that promote these pathological effects are complex. This complexity is underscored by the fact that these mediators act through many overlapping secondary messenger systems. Given this natural redundancy, many drugs used to treat PAH show short-term efficacy but fall short in the long term in reversing or halting the progression of this disease.

[0005] This redundancy in pathways justifies the use of combinations of drugs with different mechanisms of action to treat PAH. Combination therapy involving combinations of existing therapies or novel drugs with improved pharmacodynamic properties represents a new clinical paradigm for patients with suboptimal responses, further reducing the morbidity and mortality associated with PAH.

[0006] Therefore, it is clinically necessary to find combination drug combinations for the treatment of pulmonary arterial hypertension to provide more and better medication options for patients with different conditions. Summary of the invention

[0007] In view of this, the present invention provides a combined pharmaceutical composition for treating pulmonary hypertension and its application.

[0008] In order to solve the above technical problems, one object of the present invention is to provide a pharmaceutical composition, comprising a first active ingredient and a second active ingredient, wherein the first active ingredient is a PGI2 receptor agonist compound shown in general formula I or a pharmaceutically acceptable salt thereof, and the second active ingredient is sildenafil; the compound shown in general formula I or a pharmaceutically acceptable salt thereof is a PGI2 receptor agonist.

[0009]

[0010] In the formula, R1 and R2 are independently selected from H, C1-C3 alkyl or halogen atom; Z is selected from CR7 or N atom, wherein R7 is selected from H or C1-C3 alkyl, halogen atom or halogenated C1-C3 alkyl; R3 is selected from C2-C4 alkyl, C 3- C6 monocyclic cycloalkyl; R4 is selected from H, C1-C3 alkoxy or 3-6 membered heteroalicyclic group; R5 represents OH, OR6 or NHSO2R6, wherein R6 represents C 1-4 Alkyl or halogen-substituted C 1-4 Alkyl; carboxyl forms acid, ester or sulfonamide with R5; Indicates a single bond or a double bond.

[0011] In one embodiment, in the compound of the above formula I or a pharmaceutically acceptable salt thereof, Z is a N atom; or Z is CR7, and R7 is selected from H or CH3.

[0012] In one embodiment, represents a double bond, R4 is H, and accordingly, its structural formula is shown in Formula II:

[0013] In formula II, R1 and R2 are selected from H, methane or F; Z is a N atom, or Z is CR7, R7 is selected from H or CH3, more preferably H atom; R3 is selected from isopropyl, ethyl or cyclopropane, more preferably isopropyl; R5 is selected from OH or NHSO2R6, R6 is selected from C 1-4 Alkyl or halogen-substituted C 1-4 Alkyl, R6 is more preferably methyl.

[0014] In one embodiment, Represents a single bond, and its structural formula is shown in Formula III:

[0015] In formula III, R4 is selected from H, C1-C3 alkoxy or 3-6 membered heteroalicyclic group, preferably R4 is H, methoxy, ethoxy or , more preferably R4 is H, methoxy or ethoxy.

[0016] In one embodiment, the compound of formula I or III or a pharmaceutically acceptable salt thereof is provided, wherein R1 and R2 are selected from H, methane or F; Z is a N atom, or Z is CR7, R7 is selected from H or CH3, more preferably an H atom; R3 is selected from isopropyl, ethyl or cyclopropane, preferably R3 is isopropyl; and R5 is preferably OH or NHSO2CH3.

[0017] The compound of the general formula I is selected from but not limited to the specific compounds (1)-(15) shown in the structural formula below. The code names of the specific compounds are also displayed in the structural formula accordingly. Compounds (1)-(15) are named SYN001, SYN002, SYN003, SYN004, SYN005, SYN006, SYN007, SYN008, SYN013, SYN010, SYN017, SYN044, SYN046, SYN018, and SYN045, respectively.

[0018]

[0019]

[0020]

[0021]

[0022]

[0023]

[0024]

[0025]

[0026] The chemical names, preparation methods and other related information of the above-mentioned compounds of general formula I, II, and III and their pharmaceutically acceptable salts and the specific compounds (1)-(14) and their pharmaceutically acceptable salts are disclosed in the patent application document of Chinese patent application No. CN202410701014.X. The chemical names, preparation methods and other related information of the specific compound (15) and its pharmaceutically acceptable salts are disclosed in the patent application document of Chinese patent application No. CN202410701022.4.

[0027] The inventors have found through a large number of experiments that the PGI2 receptor agonist compound represented by the general formula I or the specific compounds (1)-(15) in combination with sildenafil has a strong synergistic anti-pulmonary hypertension activity, thereby achieving enhanced anti-pulmonary hypertension activity.

[0028] The PGI2 receptor agonist compound represented by the general formula I or the specific compounds (1)-(15) in combination with sildenafil has a synergistic effect in inhibiting K+-induced increase in pulmonary artery ring tension and / or inhibiting PDGF-induced proliferation of human pulmonary artery smooth muscle cells. The pharmaceutical composition is more helpful in treating patients with pulmonary hypertension that cannot be cured by a single drug.

[0029] In some embodiments, the molar ratio of the first active ingredient to the second active ingredient is 1:4-12:1; the preferred molar ratio of the first active ingredient to the second active ingredient is 1:3-10:1; the further preferred molar ratio is 1:3, 4:1 or 10:1; the more preferred molar ratio is 4:1, under which the Combination Index (CI) value is relatively lower and the synergistic effect is stronger. In some embodiments, in the pharmaceutical composition, the first active ingredient is a specific compound (1).

[0030] Furthermore, the molar ratio of the specific compound (1) to sildenafil is 1:3-10:1, preferably 1:3, 4:1 or 10:1.

[0031] In some embodiments, the first active ingredient of the pharmaceutical composition is the specific compound (2).

[0032] Furthermore, the molar ratio of the specific compound (2) to sildenafil is 1:3-10:1, preferably 1:3, 4:1 or 10:1.

[0033] In some embodiments, the pharmaceutical composition, the first active ingredient is a specific compound (3).

[0034] Furthermore, the molar ratio of the specific compound (3) to sildenafil is 1:3-10:1, preferably 1:3, 4:1 or 10:1.

[0035] In some embodiments, in the pharmaceutical composition, the first active ingredient is a specific compound (4).

[0036] Furthermore, the molar ratio of the specific compound (4) to sildenafil is 1:3-10:1, preferably the molar ratio is 1:3, 4:1 or 10:1, and more preferably the molar ratio is 10:1.

[0037] In some embodiments, the pharmaceutical composition, the first active ingredient is a specific compound (5).

[0038] Furthermore, the molar ratio of the specific compound (5) to sildenafil is 1:3-10:1, preferably the molar ratio is 1:3, 4:1 or 10:1, and more preferably the molar ratio is 1:3.

[0039] In some embodiments, the pharmaceutical composition, the first active ingredient is a specific compound (6).

[0040] Furthermore, the molar ratio of the specific compound (6) to sildenafil is 1:3-10:1, preferably the molar ratio is 1:3, 4:1 or 10:1, and more preferably the molar ratio is 4:1.

[0041] In some embodiments, the first active ingredient of the pharmaceutical composition is a specific compound (7).

[0042] Furthermore, the molar ratio of the specific compound (7) to sildenafil is 1:3-10:1, preferably the molar ratio is 1:3, 4:1 or 10:1, and more preferably the molar ratio is 10:1.

[0043] In some embodiments, the pharmaceutical composition, the first active ingredient is a specific compound (8).

[0044] Furthermore, the molar ratio of the specific compound (8) to sildenafil is 1:3-10:1, preferably the molar ratio is 1:3, 4:1 or 10:1, and more preferably the molar ratio is 1:3.

[0045] In some embodiments, the first active ingredient of the pharmaceutical composition is a specific compound (9), code name SYN013.

[0046] Furthermore, the molar ratio of the specific compound (9) to sildenafil is 1:3-10:1, preferably the molar ratio is 1:3, 4:1 or 10:1, and more preferably the molar ratio is 1:3.

[0047] In some embodiments, the pharmaceutical composition, the first active ingredient is a specific compound (10), code name SYN010.

[0048] Furthermore, the molar ratio of the specific compound (10) to sildenafil is 1:3-10:1, preferably the molar ratio is 1:3, 4:1 or 10:1, and more preferably the molar ratio is 10:1.

[0049] In some embodiments, the first active ingredient of the pharmaceutical composition is a specific compound (11), code name SYN017.

[0050] Furthermore, the molar ratio of the specific compound (11) to sildenafil is 1:3-10:1, preferably 1:3, 4:1 or 10:1.

[0051] In some embodiments, the pharmaceutical composition, the first active ingredient is a specific compound (12), code name SYN044.

[0052] Furthermore, the molar ratio of the specific compound (12) to sildenafil is 1:3-10:1, preferably the molar ratio is 1:3-4:1, and more preferably the molar ratio is 1:3 or 4:1.

[0053] In some embodiments, the pharmaceutical composition, the first active ingredient is a specific compound (13), code name SYN046.

[0054] Furthermore, the molar ratio of the specific compound (13) to sildenafil is 1:3-10:1, preferably the molar ratio is 1:3-4:1, and more preferably the molar ratio is 1:3 or 4:1.

[0055] In some embodiments, the pharmaceutical composition, the first active ingredient is a specific compound (14), code name SYN018.

[0056] Furthermore, the molar ratio of the specific compound (14) to sildenafil is 1:3-10:1, preferably the molar ratio is 1:3-4:1, and more preferably the molar ratio is 1:3 or 4:1.

[0057] In some embodiments, the pharmaceutical composition, the first active ingredient is a specific compound (15), code name SYN045.

[0058] Furthermore, the molar ratio of the specific compound (15) to sildenafil is 1:3-10:1, preferably 1:3, 4:1 or 10:1.

[0059] The synergistic effect of the PGI2 receptor agonist compound or specific compound (1)-(15) represented by the general formula I and sildenafil in combination at the above-mentioned specific ratio and test concentration on inhibiting K+-induced increase in pulmonary artery ring tension and / or inhibiting PDGF-induced proliferation of human pulmonary artery smooth muscle cells is stronger than the synergistic effect of the existing drug selexipag and sildenafil in combination. Therefore, the combined pharmaceutical composition has a better anti-pulmonary hypertension effect and is more helpful for the treatment of patients with moderate to severe pulmonary hypertension whose condition cannot be controlled by the existing drug selexipag and sildenafil in combination.

[0060] In some embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier and / or excipient; and the dosage form thereof can be tablets, granules, capsules, powders or injections.

[0061] Another object of the present invention is to provide a use of the above-mentioned pharmaceutical composition in the preparation of a combined drug for treating pulmonary hypertension. BRIEF DESCRIPTION OF THE DRAWINGS

[0062] Figure 1 This is a dot plot of the combined drug index CI in the comparative test of the ring tension inhibition rate of the isolated pulmonary artery rings in Experimental Example 1, in which the PGI2 receptor agonist compounds (1)-(15) and selexipag were combined with sildenafil (4:1); Figure 2 This is a dot plot of the combined drug index CI of the comparative test of the inhibition rate of human pulmonary artery smooth muscle cell proliferation in Experimental Example 2 in which the PGI2 receptor agonist compounds (1)-(15) and selexipag were combined with sildenafil (1:3). DETAILED DESCRIPTION

[0063] The present invention is further described in detail below through specific implementation modes, but it is only used to help understand the present invention so that professionals in the field can implement or use the present invention, and does not constitute any limitation to the present invention.

[0064] Compounds SYN001, SYN002, SYN003, SYN004, SYN005, SYN006, SYN007, SYN008, SYN013, SYN010, SYN017, SYN044, SYN046, and SYN018 were prepared respectively according to the preparation methods of Examples 1-14 in patent CN202410701014.X, and compound SYN045 was prepared according to the preparation method of Example 1 in patent CN202410701022.4.

[0065] Purchase the commercially available selexipag API from Cangzhou Enke Pharmaceutical Technology Co., Ltd., batch number 20221231; purchase the commercially available sildenafil API from Beijing Solebao Company, batch number S6070.

[0066] Example The PGI2 receptor agonist compounds SYN001, SYN002, SYN003, SYN004, SYN005, SYN006, SYN007, SYN008, SYN010, SYN013, SYN017, SYN018, SYN044, SYN045 and SYN046 were respectively formulated with sildenafil at molar ratios of 10:1, 4:1 and 1:3 to form a combined pharmaceutical composition.

[0067] The following is an in vitro pulmonary artery ring tension test and a human pulmonary artery smooth muscle cell proliferation inhibition rate test for the above-mentioned multiple combined drug compositions.

[0068] Experimental Example 1: Comparative test on tension of isolated pulmonary artery rings using a combination of PGI2 receptor agonist compounds and sildenafil 1. Experimental process: S1: Rats were anesthetized by intraperitoneal injection of 25% urethane (5 mL / kg), the heart and lungs were separated, the pulmonary artery was freed under a microscope, and a vascular ring with a length of 2-3 mm was prepared and hung on the hook of the tension transducer. The pulmonary artery ring prepared above was immersed in the incubation solution, and the basic tension of the pulmonary artery ring was finely adjusted to about 0.8-1g. The basic tension was measured after stabilization for 1-2 hours.

[0069] S2: Use high K+ incubation medium to induce increased tension in the pulmonary artery rings, and record the maximum tension induced by high K+ in the pulmonary artery rings.

[0070] S3: Then, incubation solutions and the drug combination to be tested are added to multiple incubation tanks, and as a comparison, incubation solutions containing a single drug, an incubation solution containing selexipag, and an incubation solution containing selexipag and sildenafil are prepared. The concentration of the final prepared drug in the incubation solution is shown in Table 1. The pulmonary artery vascular rings are added to the incubation solutions containing the drug solution, and the changes in the tension of the pulmonary artery rings are recorded to measure the minimum tension after the drug action.

[0071] S4: After observing the maximum drug effect, the incubation medium containing the drug solution is replaced with the basal incubation medium to restore the tension of the pulmonary artery ring to the basal level.

[0072] 2. Calculate the ring tension inhibition rate according to the following formula: .

[0073] Among them, the ring tension inhibition rate of the combination of PGI2 receptor agonist compounds and sildenafil (4:1) is shown in Table 1.

[0074] 3. By inputting the concentration of PGI2 receptor agonist compound and the corresponding ring tension inhibition rate data, the concentration of sildenafil and the corresponding ring tension inhibition rate data, the concentration of PGI2 receptor agonist compound and sildenafil combined and the corresponding ring tension inhibition rate data, the combination index CI at each ratio concentration was calculated with the help of Compusym software. The Fa-CI curve was drawn with the ring tension inhibition rate Fa of the combined use of PGI2 receptor agonist compound and sildenafil as the abscissa and the combination index CI as the ordinate.

[0075] The experimental results of the combined drug index CI are shown in Table 2, and the Fa-CI curve is shown in Figure 1 .

[0076] Table 1 Inhibition rate of ring tension of different concentrations of single-agent PGI2 receptor agonist compounds, single-agent sildenafil, and combination of PGI2 receptor agonist compounds and sildenafil (4:1) in the isolated pulmonary artery ring tension comparison test

[0077] Table 2 Combination drug index (CI) of different concentrations of PGI2 receptor agonist compounds combined with sildenafil in different proportions in the isolated pulmonary artery ring tension comparison test (n=5)

[0078] Conclusion: The combined use of PGI2 receptor agonist compounds and sildenafil was tested for the ring tension inhibition rate of isolated pulmonary artery rings at 5 concentrations at 3 ratios. When CI was less than 1, the two drugs had a synergistic effect, and the lower the CI value, the stronger the synergistic effect; when CI was equal to 1, the two drugs had an additive effect; when CI was greater than 1, the two drugs had an antagonistic effect.

[0079] At three ratios (referring to the molar ratio of PGI2 receptor agonist compound to sildenafil of 1:3, 4:1, and 10:1, the same below) and five concentrations (as shown in Table 2, referring to the five test concentrations corresponding to each PGI2 receptor agonist compound, such as SYN001 concentrations of 0.1μM, 0.2μM, 0.4μM, 0.8μM, and 1.6μM, SYN002 concentrations of 1μM, 2μM, 4μM, 8μM, and 16μM, rather than sildenafil concentrations, the sildenafil concentrations are calculated according to the corresponding combined drug ratios, the same below), the CI values ​​of SYN001, SYN002, and sildenafil are all less than 0.7, and all have synergistic effects. In particular, the CI values ​​are smaller at the five concentrations of the 4:1 ratio, and are all less than 0.6. In the control group, the CI was greater than 1 at both the ratios of 10:1 and 1:3, and most of the CIs were higher than 0.9. In the ratio of 4:1, the CI value was approximately between 0.77 and 0.96, indicating that when the molar ratio of the PGI2 receptor agonist compound to sildenafil was 1:3-10:1, the concentration of SYN001 was 0.1μM-1.6μM, and the concentration of SYN002 was 1μM-16μM, the synergistic effect of the combination of SYN001, SYN002 and sildenafil on the inhibition of ring tension of the isolated pulmonary artery ring was significantly better than that of the control group.

[0080] The CI values ​​of the combination index of SYN003, SYN004 and sildenafil at 3 ratios and 5 concentrations were all less than 0.8, and all had synergistic effects. In particular, the CI values ​​were smaller at 5 concentrations of the 4:1 ratio, and were all less than 0.7. Compared with the CI data of the comparative example, it was lower, indicating that at the molar ratio of the PGI2 receptor agonist compound to sildenafil of 1:3-10:1, the synergistic effect of the combination of SYN003, SYN004 and sildenafil on the inhibition of the ring tension of the isolated pulmonary artery ring was also significantly better than that of the comparative example at the concentration of 1μM-16μM of SYN003 and SYN004.

[0081] The CI values ​​of SYN013 and sildenafil at 5 concentrations in 3 ratios were all lower than 0.8, indicating a synergistic effect. In particular, the CI values ​​at 5 concentrations in the 4:1 ratio were even lower, all lower than 0.7. At a molar ratio of SYN013 to sildenafil of 1:3 and 5 test concentrations (SYN013 concentrations of 1μM, 2μM, 4μM, 8μM, and 16μM), the CI value was below 0.8, while the CI of the control group was between 0.94-1.04 under the same conditions. The CI value of the combination index of SYN013 and sildenafil was significantly lower than that of the control group, and the synergistic effect was significantly better than that of the control group; at a molar ratio of SYN013 to sildenafil of 4:1 and at SYN013 concentrations of 1μM, 2μM, 4μM, and 16μM, the CI of the combination index of SYN013 and sildenafil was below 0.6, while the CI of the control group was between 0.77-0.96 under the same conditions. The CI value of the combination index of SYN013 and sildenafil was significantly lower than that of the control group, and the synergistic effect was significantly better than that of the control group; When the molar ratio of SYN013 to sildenafil was 10:1 and the concentrations of SYN013 were 1 μM, 2 μM, 4 μM and 16 μM, the combination index CI of SYN013 and sildenafil was between 0.55 and 0.72, while the CI of the control group was between 0.94 and 1.04 under the same conditions. The combination index CI value of SYN013 and sildenafil was significantly lower than that of the control group, and the synergistic effect was significantly better than that of the control group, indicating that when the molar ratio of SYN013 to sildenafil was 1:3-10:1 and the concentrations of SYN013 were 1 μM-4 μM and 16 μM, or when the molar ratio of SYN013 to sildenafil was 1:3 and the concentration of SYN013 was 8 μM, the synergistic effect of the combination of SYN013 and sildenafil on the inhibition of ring tension of isolated pulmonary artery rings was significantly better than that of the control group.

[0082] At 3 ratios and 5 concentrations, the CI values ​​of SYN007, SYN010 and sildenafil were all lower than 1, and all had synergistic effects. In particular, at a ratio of 10:1 and a concentration of 32μM, the CI values ​​were 0.58 and 0.66, respectively, while the CI of the control group was 0.9 under the same conditions. At this ratio and concentration, the CI values ​​of SYN007, SYN010 and sildenafil were lower, and the synergistic effect on the inhibition of ring tension of isolated pulmonary artery rings was significantly better than that of the control group; at a ratio of 4:1, concentrations of 16μM and 32μM, the CI of SYN007, SYN010 and sildenafil was below 0.6, while the CI of the control group was around 0.8 under the same conditions. At this ratio concentration, the CI value of the combination index of SYN007, SYN010 and sildenafil is lower, and the synergistic effect is significantly better than the control; at a ratio of 1:3, concentrations of 16μM and 32μM, the CI of the combination index of SYN007, SYN010 and sildenafil is below 0.75, while the CI of the control under the same conditions is 1.02 and 0.94, respectively. At this ratio concentration, the CI value of the combination index of SYN007, SYN010 and sildenafil is lower, and the synergistic effect on the inhibition of ring tension of isolated pulmonary artery rings is significantly better than the control.

[0083] At a ratio of 1:3 and a concentration of 16 μM, the combination index CI value of SYN005 and sildenafil was 0.77, which was significantly lower than the CI value of 1.02 of the control group under the same conditions. At this ratio and concentration, the synergistic effect of the combination of SYN005 and sildenafil on the inhibition of ring tension of isolated pulmonary artery rings was significantly better than that of the control group.

[0084] At a ratio of 4:1 and a concentration of 2 μM, the CI value of the combination index of SYN006 and sildenafil was 0.81, which was significantly lower than the CI value of 0.96 of the control group under the same conditions. At this ratio and concentration, the synergistic effect of the combination of SYN006 and sildenafil on the inhibition of ring tension of isolated pulmonary artery rings was significantly better than that of the control group.

[0085] At a ratio of 1:3 and a concentration of 16 μM, the CI value of the combination index of SYN008 and sildenafil was 0.91, which was lower than the CI value of 1.02 of the control group under the same conditions. At this ratio and concentration, the synergistic effect of SYN008 and sildenafil was better than that of the control group, and the control group had no synergistic effect and had a certain antagonistic effect.

[0086] At a ratio of 4:1 and a concentration of 32 μM, the CI value of the combination index of SYN017 and sildenafil was 0.5, which was significantly lower than the CI value of 0.82 of the control under the same conditions (32 μM concentration); at a ratio of 10:1 and a concentration of 32 μM, the CI value of the combination index of SYN017 and sildenafil was 0.67, which was significantly lower than the CI value of 0.90 of the control under the same conditions; at a ratio of 1:3 and a concentration of 32 μM, the CI value of the combination index of SYN017 and sildenafil was 0.62, which was significantly lower than the CI value of 0.94 of the control under the same conditions. At the above ratios and corresponding concentrations, the synergistic effect of the combination of SYN017 and sildenafil on the inhibition of ring tension of isolated pulmonary artery rings was significantly better than that of the control.

[0087] At a ratio of 4:1 and a concentration of 32 μM, the CI value of the combination index of SYN044 and sildenafil was 0.41, which was significantly lower than the CI value of 0.82 of the control group under the same conditions. At this ratio and concentration, the synergistic effect of SYN044 and sildenafil was significantly better than that of the control group; at a ratio of 1:3 and a concentration of 32 μM, the CI value of the combination index of SYN044 and sildenafil was 0.56, which was significantly lower than the CI value of 0.94 of the control group under the same conditions. At this ratio and concentration, the synergistic effect of the combination of SYN044 and sildenafil on the inhibition of ring tension of isolated pulmonary artery rings was significantly better than that of the control group.

[0088] At a ratio of 4:1 and a concentration of 8 μM, the CI value of the combination index of SYN045 and sildenafil was 0.5, which was significantly lower than the CI value of 0.82 of the control group under the same conditions (32 μM concentration) and the CI value of 0.86 at the same concentration (8 μM concentration); at a ratio of 10:1 and a concentration of 8 μM, the CI value of the combination index of SYN045 and sildenafil was 0.65, which was significantly lower than the CI value of 0.90 of the control group under the same conditions (32 μM concentration) and the CI value of 0.94 at the same concentration; at a ratio of 1:3 and a concentration of 8 μM, the CI value of the combination index of SYN045 and sildenafil was 0.6, which was significantly lower than the CI value of 0.94 of the control group under the same conditions (32 μM concentration) and the CI value of 0.96 at the same concentration. At the above ratios and corresponding concentrations, the synergistic effect of the combination of SYN045 and sildenafil on the inhibition of ring tension of isolated pulmonary artery rings was significantly better than that of the control group.

[0089] At a ratio of 4:1 and a concentration of 4μM, the CI value of the combination index of SYN046 and sildenafil was 0.55, which was significantly lower than the CI value of 0.77 of the control group under the same conditions (16μM concentration) and the CI value of 0.89 at the same concentration (4μM concentration); at a ratio of 1:3 and a concentration of 4μM, the CI value of the combination index of SYN046 and sildenafil was 0.7, which was significantly lower than the CI value of 1.02 of the control group under the same conditions (16μM concentration) and the CI value of 0.98 at the same concentration (4μM concentration). At the above ratios and corresponding concentrations, the synergistic effect of the combination of SYN046 and sildenafil on the inhibition of ring tension of isolated pulmonary artery rings was significantly better than that of the control group.

[0090] At a ratio of 4:1 and concentrations of 16μM and 32μM, the CI values ​​of the combination index of SYN018 and sildenafil were 0.59 and 0.44, which were significantly lower than the CI values ​​of 0.77 and 0.82 of the control group under the same conditions (16μM and 32μM concentrations); at a ratio of 10:1 and a concentration of 32μM, the CI value of the combination index of SYN018 and sildenafil was 0.61, which was significantly lower than the CI value of 0.90 of the control group under the same conditions; at a ratio of 1:3 and concentrations of 16μM and 32μM, the CI values ​​of the combination index of SYN018 and sildenafil were 0.72 and 0.6, which were significantly lower than the CI values ​​of 1.02 and 0.94 of the control group under the same conditions. At the above ratios and corresponding concentrations, the synergistic effect of the combination of SYN018 and sildenafil on the inhibition of ring tension of isolated pulmonary artery rings was significantly better than that of the control group.

[0091] The above results show that the PGI2 receptor agonist compounds SYN001, SYN002, SYN003, SYN004, SYN005, SYN006, SYN007, SYN008, SYN010, SYN013, SYN017, SYN018, SYN044, SYN045, and SYN046 have a synergistic effect in inhibiting K+-induced increase in pulmonary artery ring tension when used in combination with sildenafil at the above specific ratios and test concentrations, and the synergistic effect is better than that of selexipag combined with sildenafil. The synergistic effect of YN003, SYN004 and SYN013 in combination with sildenafil is more prominent, and the synergistic effect at 3 ratios and 5 test concentrations is better than that of the control example, indicating that the synergistic effect of SYN001, SYN002, SYN003, SYN004 and SYN013 in combination with sildenafil at a molar ratio of 1:3-10:1, SYN001 at a concentration of 0.1μM-1.6μM, and SYN002, SYN003, SYN004 and SYN013 at a concentration of 1μM-16μM on the inhibition of proliferation of human pulmonary artery smooth muscle cells is very significant.

[0092] Experimental Example 2: Comparative study on the inhibition rate of human pulmonary artery smooth muscle cell proliferation by combined use of PGI2 receptor agonist compounds and sildenafil The drug efficacy is evaluated through cell models. Excessive proliferation and migration of pulmonary artery smooth muscle cells (PASMCs) are prominent features of vascular remodeling. In PAH, pulmonary vascular smooth muscle cells transform from a contractile phenotype to a synthetic phenotype of a proliferative state, which is mainly manifested as proliferation and hypertrophy of pulmonary vascular smooth muscle cells. The above pathological changes ultimately lead to stenosis of the pulmonary vascular lumen and reduced compliance of the vessel wall, which in turn promotes the occurrence and development of PAH. Therefore, PASMCs can be used to evaluate drug screening for pulmonary hypertension. The PDGF-induced human pulmonary artery smooth muscle cell proliferation model is a classic model for evaluating therapeutic drugs for pulmonary hypertension at the cellular level.

[0093] The experimental drugs PGI2 receptor agonist compounds SYN001, SYN002, SYN003, SYN004, SYN005, SYN006, SYN007, SYN008, SYN010, SYN013, SYN017, SYN018, SYN044, SYN045, SYN046 and the control drug PGI2 receptor agonist selexipag were used in combination with sildenafil at molar ratios of 10:1, 4:1, and 1:3, respectively, to conduct a comparative test on the inhibition rate of human pulmonary artery smooth muscle cell proliferation, so as to investigate the effect of the combination of PGI2 receptor agonist compounds and sildenafil on the proliferation of human pulmonary artery smooth muscle cells induced by PDGF.

[0094] Experimental process: Preparation of control group: human pulmonary artery smooth muscle cells were digested with 0.25% trypsin solution, seeded in a 96-well plate at 6×103 / well (final volume of 100 μL) and cultured for 24 h. Then, they were starved with serum-free Dulbecco's modified eagle medium (DMEM) high-glucose medium for 24 h, and 100 μL DMEM was added again and cultured for 24 h to obtain the control group.

[0095] Model group preparation: Human pulmonary artery smooth muscle cells were digested with 0.25% trypsin solution, inoculated in 96-well plates at 6×103 / well (final volume of 100μL) and cultured for 24h, then starved for 24h with serum-free Dulbecco's modified eagle medium (DMEM) high glucose medium. DMEM containing human platelet-derived growth factor (hPDGF-BB) at a final concentration of 20ng / mL was added in a volume of 100μL and cultured for 24h to obtain the model group.

[0096] Preparation of the test group: Human pulmonary artery smooth muscle cells were digested with 0.25% trypsin solution, seeded in 96-well plates at 6×103 / well (final volume of 100 μL) and cultured for 24 hours, and then starved for 24 hours with serum-free Dulbecco's modified eagle medium (DMEM) high glucose medium. Human platelet-derived growth factor (hPDGF-BB) was added to DMEM to make its final concentration 20 ng / mL, and then the pre-prepared PGI2 receptor agonist compound single drug solution, sildenafil single drug solution, and PGI2 receptor agonist compound and sildenafil combined drug solution of different concentrations were gradiently diluted with DMEM containing hPDGF-BB to the concentrations shown in Tables 3 and 4 to obtain the test solution, and the test solution was added to the cell culture well after starvation treatment in a volume of 100 μL, and cultured for 24 hours to obtain the test group.

[0097] The CellTiter-Glo reagent was added into the culture wells of the test group, control group and model group, the luminescence value was measured, the cell viability was detected, and the cell proliferation inhibition rate was calculated.

[0098] The cell proliferation inhibition rate was calculated by the following formula: .

[0099] By inputting the concentration of PGI2 receptor agonist compound and the corresponding cell proliferation inhibition rate data, the concentration of sildenafil and the corresponding cell proliferation inhibition rate data, the concentration of the combination of PGI2 receptor agonist compound and sildenafil and the corresponding cell proliferation inhibition rate data, the combination index CI at each ratio concentration was calculated with the help of Compusym software, and the Fa-CI curve was drawn with the cell proliferation inhibition rate Fa of the combination of PGI2 receptor agonist compound and sildenafil as the horizontal axis and the combination index CI as the vertical axis.

[0100] The experimental results are shown in Table 3, Table 4, Figure 2 .

[0101] Table 3 The cell proliferation inhibition rates of different concentrations of single-agent PGI2 receptor agonist compounds, single-agent sildenafil, and the combination of PGI2 receptor agonist compounds and sildenafil (1:3) in the comparison test of the proliferation inhibition rate of human pulmonary artery smooth muscle cells

[0102] Table 4 Combination drug index CI of different concentrations of PGI2 receptor agonist compounds combined with sildenafil in different proportions in the comparison test of human pulmonary artery smooth muscle cell proliferation inhibition rate (n=5)

[0103] Conclusion: The combined use of PGI2 receptor agonist compounds and sildenafil at three ratios and five concentrations tested the combined index CI for the inhibition rate of human pulmonary artery smooth muscle cell proliferation. When the CI is less than 1, the two drugs have a synergistic effect, and the lower the CI value, the stronger the synergistic effect; when the CI is equal to 1, the two drugs have an additive effect; when the CI is greater than 1, the two drugs have an antagonistic effect.

[0104] At 3 ratios (PGI2 receptor agonist compound to sildenafil molar ratio of 1:3, 4:1, 10:1, the same below) and 5 concentrations (as shown in Table 4, it refers to the 5 tested concentrations of PGI2 receptor agonist compounds, such as SYN005 concentrations of 0.1μM, 0.3μM, 0.9μM, 2.7μM, 8.1μM, not the sildenafil concentration, the sildenafil concentration is calculated according to the corresponding combined drug ratio, the same below), the CI values ​​of the combination index of SYN005 and sildenafil are all less than 0.7, and all have synergistic effects. In particular, the CI values ​​are smaller at the 5 concentrations of the 4:1 ratio, and are all less than 0.6. In the control group, the CI was greater than 1 at the ratios of 1:3 and 10:1, and most of the CI values ​​were close to 0.9 or higher. In the ratio of 4:1, the CI value was approximately between 0.68 and 0.87, and under the same conditions, the CI value was significantly higher than that of the combination of SYN005 and sildenafil, indicating that the synergistic effect of the combination of SYN005 and sildenafil on the inhibition of proliferation of human pulmonary artery smooth muscle cells was significantly better than that of the control group when the molar ratio of PGI2 receptor agonist compound to sildenafil was 1:3-10:1 and the concentration of PGI2 receptor agonist compound was 0.1μM-8.1μM.

[0105] At 5 concentrations in 3 ratios, the CI values ​​of the combination index of SYN001, SYN018 and sildenafil were all no higher than 0.8, and all had synergistic effects. In particular, the CI values ​​were smaller at 5 concentrations of the 4:1 ratio, and all were no higher than 0.65. Under the same conditions, the CI data was lower than that of the comparative example, indicating that the synergistic effect of the combination of SYN001, SYN018 and sildenafil on the inhibition of proliferation of human pulmonary artery smooth muscle cells was also significantly better than that of the comparative example when the molar ratio of the PGI2 receptor agonist compound to sildenafil was 1:3-10:1 and the concentration of the PGI2 receptor agonist compound was 0.1μM-8.1μM.

[0106] The CI values ​​of the combination index of SYN002 and sildenafil at 3 ratios and 5 concentrations were all less than 1, indicating a synergistic effect. In particular, at 3 ratios and a concentration of 8.1 μM, the CI values ​​were all less than 0.5, and were lower than the CI data of the comparative example under the same conditions, indicating that the synergistic effect of SYN002 and sildenafil on the inhibition of proliferation of human pulmonary artery smooth muscle cells was significantly better than that of the comparative example when the molar ratio of the PGI2 receptor agonist compound to sildenafil was 1:3-10:1 and the concentration of the PGI2 receptor agonist compound was 8.1 μM.

[0107] The CI values ​​of the combination index of SYN003 and sildenafil at 3 ratios and 5 concentrations were all no higher than 0.85, indicating that there was a synergistic effect. In particular, at 3 ratios, 0.1 μM and 2.7 μM concentrations, the CI values ​​were no higher than 0.81, and were lower than the CI data of the comparative example under the same conditions, indicating that the synergistic effect of SYN003 and sildenafil on the inhibition of proliferation of human pulmonary artery smooth muscle cells was also significantly better than that of the comparative example when the molar ratio of the PGI2 receptor agonist compound to sildenafil was 1:3-10:1 and the concentration of the PGI2 receptor agonist compound was 0.1 μM and 2.7 μM.

[0108] The CI value of the combination index of SYN004 and sildenafil at multiple ratios and multiple test concentrations exceeded 1, indicating no synergistic effect. However, at a ratio of 10:1 and a concentration of 0.1 μM, its CI value was 0.82, which was significantly lower than the CI value of 1.02 of the control under the same conditions, indicating that at a ratio of 10:1 and a concentration of 0.1 μM of the PGI2 receptor agonist compound, the synergistic effect of SYN004 combined with sildenafil on the inhibition of proliferation of human pulmonary artery smooth muscle cells was also significantly better than that of the control.

[0109] The CI value of the combination index of SYN006 with sildenafil at a certain test concentration in multiple ratios exceeded 1, indicating no synergistic effect. However, at 3 ratios and a concentration of 2.7 μM, its CI value was no higher than 0.71, and was lower than the CI data of the comparative example under the same conditions, indicating that the synergistic effect of SYN006 combined with sildenafil on the inhibition of proliferation of human pulmonary artery smooth muscle cells was also significantly better than that of the comparative example at a molar ratio of PGI2 receptor agonist compound to sildenafil of 1:3-10:1 and a concentration of PGI2 receptor agonist compound of 2.7 μM.

[0110] The CI values ​​of the combination index of SYN007 and sildenafil at 3 ratios and 5 concentrations were all no higher than 0.85, indicating that there was a synergistic effect. In particular, at 3 ratios, 0.1 μM and 8.1 μM concentrations, the CI values ​​were no higher than 0.61, and were lower than the CI data of the comparative example under the same conditions, indicating that the synergistic effect of SYN007 and sildenafil on the inhibition of proliferation of human pulmonary artery smooth muscle cells was also significantly better than that of the comparative example when the molar ratio of the PGI2 receptor agonist compound to sildenafil was 1:3-10:1 and the concentration of the PGI2 receptor agonist compound was 0.1 μM and 8.1 μM.

[0111] The CI values ​​of the combination index of SYN008, SYN010 and sildenafil at 3 ratios and 5 concentrations were all no higher than 0.85, and all had synergistic effects. In particular, at 3 ratios, 0.1 μM and 0.3 μM concentrations, the CI values ​​were no higher than 0.75, and were lower than the CI data of the comparative example under the same conditions, indicating that the synergistic effect of SYN008, SYN010 and sildenafil on the inhibition of proliferation of human pulmonary artery smooth muscle cells was also significantly better than that of the comparative example when the molar ratio of PGI2 receptor agonist compound to sildenafil was 1:3-10:1 and the concentration of PGI2 receptor agonist compound was 0.1 μM and 0.3 μM.

[0112] The CI value of the combination index of SYN013 and sildenafil at a certain ratio and a certain test concentration is 1, indicating no synergistic effect. However, at 3 ratios, concentrations of 2.7μM and 8.1μM, the CI values ​​were all no higher than 0.75, and were lower than the CI data of the comparative example under the same conditions, indicating that the synergistic effect of SYN013 and sildenafil on the inhibition of proliferation of human pulmonary artery smooth muscle cells at a molar ratio of PGI2 receptor agonist compound to sildenafil of 1:3-10:1 and a concentration of PGI2 receptor agonist compound of 2.7μM and 8.1μM was also significantly better than that of the comparative example.

[0113] The CI value of the combination index of SYN017 and sildenafil at a certain ratio and a certain test concentration exceeded 1, indicating no synergistic effect. However, at three ratios and a concentration of 0.3 μM, its CI value was no higher than 0.7, and was lower than the CI data of the comparative example under the same conditions, indicating that the synergistic effect of SYN017 and sildenafil on the inhibition of proliferation of human pulmonary artery smooth muscle cells was significantly better than that of the comparative example when the molar ratio of PGI2 receptor agonist compound to sildenafil was 1:3-10:1 and the concentration of PGI2 receptor agonist compound was 0.3 μM.

[0114] The CI values ​​of the combination index of SYN044, SYN045 and sildenafil at 3 ratios and 5 concentrations were all less than 1, and all had synergistic effects. In particular, at 3 ratios and a concentration of 0.1 μM, the CI values ​​were all less than 0.81, and were lower than the CI data of the comparative example under the same conditions, indicating that the synergistic effect of SYN044, SYN045 and sildenafil on the inhibition of proliferation of human pulmonary artery smooth muscle cells was also significantly better than that of the comparative example when the molar ratio of the PGI2 receptor agonist compound to sildenafil was 1:3-10:1 and the concentration of the PGI2 receptor agonist compound was 0.1 μM.

[0115] The CI values ​​of the combination index of SYN046 and sildenafil at 3 ratios and 5 concentrations were all less than 1, indicating a synergistic effect. In particular, at 3 ratios and a concentration of 2.7 μM, the CI values ​​were all less than 0.52, and were lower than the CI data of the comparative example under the same conditions, indicating that the synergistic effect of SYN046 and sildenafil on the inhibition of proliferation of human pulmonary artery smooth muscle cells was significantly better than that of the comparative example when the molar ratio of the PGI2 receptor agonist compound to sildenafil was 1:3-10:1 and the concentration of the PGI2 receptor agonist compound was 2.7 μM.

[0116] The above results indicate that the PGI2 receptor agonist compounds SYN001, SYN002, SYN003, SYN004, SYN005, SYN006, SYN007, SYN008, SYN010, SYN013, SYN017, SYN018, SYN044, SYN045, and SYN046, when used in combination with sildenafil at the above specific ratios and test concentrations, have a synergistic effect on inhibiting PDGF-induced proliferation of human pulmonary artery smooth muscle cells, and the synergistic effect It is better than the combination of selexipag and sildenafil, among which the synergistic effect of SYN001, SYN005 and SYN018 in combination with sildenafil is more prominent, and the synergistic effects at 3 ratios and 5 test concentrations are all better than those of the control example, indicating that the synergistic effect of SYN001, SYN005 and SYN018 and sildenafil in combination at a molar ratio of 1:3-10:1 and a PGI2 receptor agonist compound concentration of 0.1μM-8.1μM on the inhibition of proliferation of human pulmonary artery smooth muscle cells is very significant.

[0117] In summary, the PGI2 receptor agonist compounds SYN001, SYN002, SYN003, SYN004, SYN005, SYN006, SYN007, SYN008, SYN010, SYN013, SYN017, SYN018, SYN044, SYN045, and SYN046, when used in combination with sildenafil at the above-mentioned specific ratios and test concentrations, have a synergistic effect in inhibiting K+-induced increase in pulmonary artery ring tension and / or inhibiting PDGF-induced proliferation of human pulmonary artery smooth muscle cells, and the synergistic effect is better than that of selexipag combined with sildenafil.

[0118] Among them, the synergistic effect of SYN001, SYN002, SYN003, SYN004 and SYN013 combined with sildenafil on inhibiting K+-induced increase in pulmonary artery ring tension is more prominent, and the synergistic effect at 3 ratios and 5 test concentrations is better than the control example. The synergistic effect of SYN001, SYN005 and SYN018 combined with sildenafil on inhibiting PDGF-induced proliferation of human pulmonary artery smooth muscle cells is more prominent, and the synergistic effect at 3 ratios and 5 test concentrations is better than the control example. Therefore, compound SYN001 has outstanding synergistic effects in both aspects, and has a strong synergistic effect on inhibiting K+-induced increase in pulmonary artery ring tension, and also has a strong synergistic effect on inhibiting PDGF-induced proliferation of human pulmonary artery smooth muscle cells. The above-mentioned PGI2 receptor agonist compounds and sildenafil have broad application prospects in the combined use of drugs for the treatment of pulmonary hypertension.

[0119] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modification, equivalent substitution or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A pharmaceutical composition, characterized in that It comprises a first active ingredient and a second active ingredient, wherein the first active ingredient is a PGI2 receptor agonist compound represented by general formula I or a pharmaceutically acceptable salt thereof, and the second active ingredient is sildenafil; In the formula, R1 and R2 are independently selected from H, C1-C3 alkyl or halogen atom; Z is selected from CR7 or N atom, wherein R7 is selected from H or C1-C3 alkyl, halogen atom or halogenated C1-C3 alkyl; R3 is selected from C2-C4 alkyl, C 3- C6 monocyclic cycloalkyl; R4 is selected from H, C1-C3 alkoxy or 3-6 membered heteroalicyclic group; R5 represents OH, OR6 or NHSO2R6, wherein R6 represents C 1-4 Alkyl or halogen-substituted C 1-4 alkyl; Indicates a single bond or a double bond.

2. The pharmaceutical composition according to claim 1, characterized in that The first active ingredient is selected from the specific compounds (1)-(15) shown below in the structural formula: 。 3. The pharmaceutical composition according to any one of claims 1 to 2, characterized in that The molar ratio of the first active ingredient to the second active ingredient is 1:4-12:

1.

4. The pharmaceutical composition according to claim 3, characterized in that The molar ratio of the first active ingredient to the second active ingredient is 1:3-10:

1.

5. The pharmaceutical composition according to claim 4, characterized in that The molar ratio of the first active ingredient to the second active ingredient is 1:3, 4:1 or 10:

1.

6. The pharmaceutical composition according to claim 5, characterized in that The first active ingredient is the specific compound (1), and the molar ratio of the specific compound (1) to sildenafil is 1:3, 4:1 or 10:1; or The first active ingredient is the specific compound (2), and the molar ratio of the specific compound (2) to sildenafil is 1:3, 4:1 or 10:1; or The first active ingredient is the specific compound (3), and the molar ratio of the specific compound (3) to sildenafil is 1:3, 4:1 or 10:1; or The first active ingredient is a specific compound (11), and the molar ratio of the specific compound (11) to sildenafil is 1:3, 4:1 or 10:1; or The first active ingredient is a specific compound (15), and the molar ratio of the specific compound (15) to sildenafil is 1:3, 4:1 or 10:

1.

7. The pharmaceutical composition according to claim 5, characterized in that The first active ingredient is a specific compound (12), and the molar ratio of the specific compound (12) to sildenafil is 1:3 or 4:1; or The first active ingredient is a specific compound (13), and the molar ratio of the specific compound (13) to sildenafil is 1:3 or 4:1; or The first active ingredient is a specific compound (14), and the molar ratio of the specific compound (14) to sildenafil is 1:3 or 4:

1.

8. The pharmaceutical composition according to claim 5, characterized in that The first active ingredient is the specific compound (4), and the molar ratio of the specific compound (4) to sildenafil is 10:1; or The first active ingredient is the specific compound (5), and the molar ratio of the specific compound (5) to sildenafil is 1:3; or The first active ingredient is the specific compound (6), and the molar ratio of the specific compound (6) to sildenafil is 4:1; or The first active ingredient is the specific compound (7), and the molar ratio of the specific compound (7) to sildenafil is 10:1; or The first active ingredient is the specific compound (8), and the molar ratio of the specific compound (8) to sildenafil is 1:3; or The first active ingredient is the specific compound (9), and the molar ratio of the specific compound (9) to sildenafil is 1:3; or The first active ingredient is a specific compound (10), and the molar ratio of the specific compound (10) to sildenafil is 10:

1.

9. The pharmaceutical composition according to any one of claims 1-2, 4-8, characterized in that: It also includes acceptable carriers and / or excipients, and the pharmaceutical composition is in the form of tablets, granules, capsules, powders or injections.

10. Use of the pharmaceutical composition according to any one of claims 1 to 9 in the preparation of a combined drug for treating pulmonary arterial hypertension.

Citation Information

Patent Citations

  • Diphenyltriazine compound as well as preparation method and application thereof

    CN118598820A

  • PGI2 receptor agonist compound, pharmaceutical composition and application

    CN118619893A

  • Heterocyclic derivatives and medicines

    CN1516690A

  • Iloprost in combination therapies for the treatment of pulmonary arterial hypertension

    CN1856339A

Cited By

  • PGI2 receptor agonist compound, pharmaceutical composition and application

    CN118619893A

  • Pgi2 receptor agonist compounds, pharmaceutical compositions and uses

    CN118619893B

  • PGI2 receptor agonist compound, pharmaceutical composition, and use

    WO2025139401A1